U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07724782) titled 'Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL' on July 07.
Brief Summary: This is a single-arm, multi-cohort, multicenter, phase Ib/IIa clinical study designed to evaluate the safety and efficacy of Zeprumetostat (an EZH2 inhibitor) in combination with different therapeutic agents/regimens - specifically, the JAK1 inhibitor golidocitinib and the GemOx chemotherapy regimen (gemcitabine plus oxaliplatin) - in patients with relapsed or refractory peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and T-follicular helper cell lymphoma (TFHL). The trial comprises a phase Ib dose-escalation phas...